SHISA3

Across TCGA pan-cancer cohorts, SHISA3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SHISA3 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in pheochromocytoma and paraganglioma (PCPG), where higher SHISA3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SHISA3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

PCPG, DLBC, and LIHC are the cancer types where SHISA3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PCPG	OS	Median	All	0.009	0.946	<.001	12	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.736	0.220	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SHISA3–PCPG (OS)

Open the PCPG breakdown →